Skip to main content
. 2023 Mar 15;133(6):e166032. doi: 10.1172/JCI166032

Figure 1. Immunocompromised and Omicron-infected COVID-19 patients display higher viral loads after mAb administration.

Figure 1

RT-qPCR detection of SARS-CoV-2 was performed on nasopharyngeal swab samples collected on D0, D2, and D7 from patients treated with different therapeutic mAbs. (A) A steady increase in Ct values was observed over 7 days for all mAb-treated groups. Box-and-whisker plots indicate median (middle line), 25th and 75th percentiles (box boundary), and 5th and 95th percentiles (whiskers). All data points, including outliers, are displayed. (B) Overall, patients carrying Omicron (BA.1, BA1+R346K, or BA.2) displayed higher viral loads than patients carrying Alpha subvariants (B.1.1.7 or Q4). (C) Immunocompromised patients carried higher viral loads, irrespective of the infecting SARS-CoV-2 variant and mAb treatment. Line graphs in B and C represent smoothed conditional means, with shaded areas displaying 95% CIs for all measured time points. Cross-sectional and longitudinal statistical comparisons were performed using Mann-Whitney followed by Bonferroni’s post hoc correction. *P < 0.05; **P < 0.01; ***P < 0.001. NS, nonsignificant; D0, sample collected prior to mAb infusion; D2, 2 ± 1 days after mAb infusion; D7, 7 ± 2 days after mAb infusion. A limited number of nasopharyngeal swab samples were collected on D28 (n = 9) across all 4 mAb therapy groups and were therefore excluded from this analysis. See Supplemental Tables 2 and 3 for details on Ct values at each time point.